Effect of Serelaxin Versus Standard of Care in Acute Heart Failure (AHF) Patients

Acute Heart Failure (AHF) Clinical Trial

— RELAX-AHF-EU  

Official title:

A Multicenter, Prospective, Randomized, Open-label Study to Assess the Effect of Serelaxin Versus Standard of Care in Acute Heart Failure (AHF) Patients

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT02064868
• Other study ID #: CRLX030A3301
• Secondary ID: 2013-002513-35
• Status: Terminated
• Phase: Phase 3
• Start date: January 31, 2014
• Est. completion date: April 25, 2017

Study information

• Verified date: December 2018
• Source: Novartis
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This was a multinational, multicenter, randomized, open-label study to confirm and expand the efficacy, safety and tolerability evidence of 48 hours intravenous infusion of serelaxin (30 micrograms/kg/day) when added to Standard of Care (SoC) in patients admitted to hospital for Acute Heart Failure (AHF).

Description:

This study was aimed at generating clinical evidence, especially on the short term period (in-hospital and at 30 days) to complement existing and future serelaxin data sets in Acute Heart Failure (AHF).

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 2666
• Est. completion date: April 25, 2017
• Est. primary completion date: March 26, 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Systolic blood pressure = 125 mmHg

• Admitted for Acute Heart Failure (AHF)

• Received intravenous furosemide (or equivalent) at any time between presentation and the start of screening

• eGFR on admission: = 25 and =75 mL/min/1.73 m^2

Exclusion Criteria:

• Dyspnea (non-cardiac causes)

• T > 38.5°C

• Clinical evidence of acute coronary syndrome currently or within 30 days prior to enrollment.

• Significant left ventricular outflow obstruction, uncorrected, such as obstructive hypertrophic cardiomyopathy or severe aortic stenosis (i.e., aortic valve area <1.0 cm^2 or mean gradient >50 mmHg on prior or current echocardiogram), severe aortic regurgitation and severe mitral stenosis.

• AHF due to significant arrhythmias

• Acute myocarditis or hypertrophic obstructive, restrictive, or constrictive cardiomyopathy (does not include restrictive mitral filling patterns seen on Doppler echocardiographic assessments of diastolic function).

Related Conditions & MeSH terms

• Acute Heart Failure (AHF)
• Heart Failure

Intervention

Drug:
• Serelaxin
30 µg/kg/day IV infusion
• Standard of Care
This treatment can include but is not limited to intravenous and/or oral diuretics, angiotensin-converting enzyme (ACE) inhibitors/angiotensin receptor antagonists, beta blockers and aldosterone receptor antagonists, etc.

Locations

Country	Name	City	State
Austria	Novartis Investigative Site	Feldkirch
Austria	Novartis Investigative Site	Graz
Austria	Novartis Investigative Site	Linz
Austria	Novartis Investigative Site	Salzburg
Austria	Novartis Investigative Site	Salzburg
Austria	Novartis Investigative Site	St. Poelten
Austria	Novartis Investigative Site	Vienna
Austria	Novartis Investigative Site	Vienna
Austria	Novartis Investigative Site	Wien
Belgium	Novartis Investigative Site	Aalst
Belgium	Novartis Investigative Site	Brugge
Belgium	Novartis Investigative Site	Brussel
Belgium	Novartis Investigative Site	Gent
Belgium	Novartis Investigative Site	Hasselt
Belgium	Novartis Investigative Site	Leuven
Belgium	Novartis Investigative Site	Liege
Belgium	Novartis Investigative Site	Lodelinsart
Belgium	Novartis Investigative Site	Mol
Belgium	Novartis Investigative Site	Mons
Belgium	Novartis Investigative Site	Roeselare
Belgium	Novartis Investigative Site	Ronse
Belgium	Novartis Investigative Site	Turnhout
Bulgaria	Novartis Investigative Site	Gabrovo
Bulgaria	Novartis Investigative Site	Plovdiv
Bulgaria	Novartis Investigative Site	Ruse
Bulgaria	Novartis Investigative Site	Sliven
Bulgaria	Novartis Investigative Site	Sofia
Bulgaria	Novartis Investigative Site	Sofia
Bulgaria	Novartis Investigative Site	Veliko Tarnovo
Croatia	Novartis Investigative Site	Varazdin	HRV
Croatia	Novartis Investigative Site	Zagreb
Czechia	Novartis Investigative Site	Brno	Czech Republic
Czechia	Novartis Investigative Site	Decin II	Czech Republic
Czechia	Novartis Investigative Site	Karvina-Raj	Czech Republic
Czechia	Novartis Investigative Site	Kromeriz	Czech Republic
Czechia	Novartis Investigative Site	Melnik	Czech Republic
Czechia	Novartis Investigative Site	Pisek	Czech Republic
Czechia	Novartis Investigative Site	Plzen
Czechia	Novartis Investigative Site	Prague 5
Czechia	Novartis Investigative Site	Svitavy	Czech Republic
Czechia	Novartis Investigative Site	Tabor	Czech Republic
Czechia	Novartis Investigative Site	Trebic	Czech Republic
Estonia	Novartis Investigative Site	Tallinn
Estonia	Novartis Investigative Site	Tartu
Finland	Novartis Investigative Site	Turku
France	Novartis Investigative Site	Abbeville
France	Novartis Investigative Site	Agen Cedex 9
France	Novartis Investigative Site	Amiens cedex 1
France	Novartis Investigative Site	Avignon
France	Novartis Investigative Site	Belfort
France	Novartis Investigative Site	Besancon Cedex
France	Novartis Investigative Site	Brest
France	Novartis Investigative Site	Bron
France	Novartis Investigative Site	Chalon sur Saône
France	Novartis Investigative Site	Chambray-lès-Tours
France	Novartis Investigative Site	Chateauroux
France	Novartis Investigative Site	Clermont-Ferrand
France	Novartis Investigative Site	Corbeil Essonnes
France	Novartis Investigative Site	Dunkerque
France	Novartis Investigative Site	La Seyne sur mer
France	Novartis Investigative Site	Le Coudray
France	Novartis Investigative Site	Le Mans Cedex 09
France	Novartis Investigative Site	Lens
France	Novartis Investigative Site	Limoges Cedex
France	Novartis Investigative Site	Lorient Cedex
France	Novartis Investigative Site	Marseille cedex 20	Bouches Du Rhone
France	Novartis Investigative Site	Metz
France	Novartis Investigative Site	Montauban
France	Novartis Investigative Site	Montauban
France	Novartis Investigative Site	Montpellier
France	Novartis Investigative Site	Mulhouse cedex
France	Novartis Investigative Site	Nancy	Cedex
France	Novartis Investigative Site	Nimes Cedex 09
France	Novartis Investigative Site	Niort
France	Novartis Investigative Site	Orleans
France	Novartis Investigative Site	Paris
France	Novartis Investigative Site	Paris
France	Novartis Investigative Site	Paris cedex 10
France	Novartis Investigative Site	Pau
France	Novartis Investigative Site	Périgueux
France	Novartis Investigative Site	Poitiers
France	Novartis Investigative Site	Rennes Cedex 9
France	Novartis Investigative Site	Saint Brieuc
France	Novartis Investigative Site	St Michel
France	Novartis Investigative Site	St Priest en Jarez Cedex
France	Novartis Investigative Site	Strasbourg Cedex
France	Novartis Investigative Site	Troyes
France	Novartis Investigative Site	Vienne
Germany	Novartis Investigative Site	Arnstadt
Germany	Novartis Investigative Site	Bad Berka
Germany	Novartis Investigative Site	Bad Oeynhausen
Germany	Novartis Investigative Site	Baden-Baden
Germany	Novartis Investigative Site	Berlin
Germany	Novartis Investigative Site	Berlin
Germany	Novartis Investigative Site	Berlin
Germany	Novartis Investigative Site	Berlin
Germany	Novartis Investigative Site	Berlin
Germany	Novartis Investigative Site	Bernburg
Germany	Novartis Investigative Site	Bochum
Germany	Novartis Investigative Site	Buchholz in der Nordheide
Germany	Novartis Investigative Site	Chemnitz
Germany	Novartis Investigative Site	Chemnitz
Germany	Novartis Investigative Site	Dorsten
Germany	Novartis Investigative Site	Dortmund
Germany	Novartis Investigative Site	Dortmund
Germany	Novartis Investigative Site	Dortmund
Germany	Novartis Investigative Site	Dresden
Germany	Novartis Investigative Site	Duisburg
Germany	Novartis Investigative Site	Duisburg
Germany	Novartis Investigative Site	Düssledorf
Germany	Novartis Investigative Site	Erfurt
Germany	Novartis Investigative Site	Erfurt
Germany	Novartis Investigative Site	Erlangen
Germany	Novartis Investigative Site	Eschwege
Germany	Novartis Investigative Site	Esslingen
Germany	Novartis Investigative Site	Flensburg	Schleswig Holstein
Germany	Novartis Investigative Site	Frankfurt
Germany	Novartis Investigative Site	Frankfurt
Germany	Novartis Investigative Site	Friesoythe
Germany	Novartis Investigative Site	Gera
Germany	Novartis Investigative Site	Gotha
Germany	Novartis Investigative Site	Greifswald
Germany	Novartis Investigative Site	Guetersloh
Germany	Novartis Investigative Site	Hamburg
Germany	Novartis Investigative Site	Heidelberg
Germany	Novartis Investigative Site	Heidenheim
Germany	Novartis Investigative Site	Hennigsdorf
Germany	Novartis Investigative Site	Herford
Germany	Novartis Investigative Site	Hoyerswerda
Germany	Novartis Investigative Site	Kaufbeuren
Germany	Novartis Investigative Site	Koblenz
Germany	Novartis Investigative Site	Koeln-Nippes
Germany	Novartis Investigative Site	Langen
Germany	Novartis Investigative Site	Lemgo
Germany	Novartis Investigative Site	Leverkusen
Germany	Novartis Investigative Site	Lüneburg
Germany	Novartis Investigative Site	Mannheim
Germany	Novartis Investigative Site	Marburg
Germany	Novartis Investigative Site	Marl
Germany	Novartis Investigative Site	Memmingen
Germany	Novartis Investigative Site	Moenchengladbach
Germany	Novartis Investigative Site	Muelheim
Germany	Novartis Investigative Site	Muenchen
Germany	Novartis Investigative Site	Neumünster
Germany	Novartis Investigative Site	Neunkirchen
Germany	Novartis Investigative Site	Neuss
Germany	Novartis Investigative Site	Neustadt A.d. Aisch
Germany	Novartis Investigative Site	Neuwied
Germany	Novartis Investigative Site	Nürnberg
Germany	Novartis Investigative Site	Ribnitz-Damgarten
Germany	Novartis Investigative Site	Rostock
Germany	Novartis Investigative Site	Rotenburg
Germany	Novartis Investigative Site	Schoenebeck
Germany	Novartis Investigative Site	Schwabach
Germany	Novartis Investigative Site	Schwalmstadt
Germany	Novartis Investigative Site	Singen
Germany	Novartis Investigative Site	Soest
Germany	Novartis Investigative Site	Sonneberg
Germany	Novartis Investigative Site	Speyer
Germany	Novartis Investigative Site	Stade
Germany	Novartis Investigative Site	Stadtlohn
Germany	Novartis Investigative Site	Stuttgart
Germany	Novartis Investigative Site	Suhl
Germany	Novartis Investigative Site	Torgau
Germany	Novartis Investigative Site	Trier
Germany	Novartis Investigative Site	Tuebingen
Germany	Novartis Investigative Site	Ulm
Germany	Novartis Investigative Site	Vechta
Germany	Novartis Investigative Site	Wesel
Germany	Novartis Investigative Site	Witten
Germany	Novartis Investigative Site	Worms
Germany	Novartis Investigative Site	Wuerzburg
Germany	Novartis Investigative Site	Wuppertal
Germany	Novartis Investigative Site	Wurzen
Greece	Novartis Investigative Site	Alexandroupolis	Evros
Greece	Novartis Investigative Site	Athens
Greece	Novartis Investigative Site	Athens
Greece	Novartis Investigative Site	Athens
Greece	Novartis Investigative Site	Volos
Greece	Novartis Investigative Site	Voula	GR
Hungary	Novartis Investigative Site	Budapest
Hungary	Novartis Investigative Site	Budapest
Hungary	Novartis Investigative Site	Budapest
Hungary	Novartis Investigative Site	Budapest
Hungary	Novartis Investigative Site	Debrecen
Hungary	Novartis Investigative Site	Eger
Hungary	Novartis Investigative Site	Gyor
Hungary	Novartis Investigative Site	Kalocsa
Hungary	Novartis Investigative Site	Kecskemet
Hungary	Novartis Investigative Site	Kistarcsa
Hungary	Novartis Investigative Site	Mako
Hungary	Novartis Investigative Site	Szeged
Hungary	Novartis Investigative Site	Szolnok
Iceland	Novartis Investigative Site	Reykjavik
Italy	Novartis Investigative Site	Acquaviva delle Fonti	BA
Italy	Novartis Investigative Site	Altamura	BA
Italy	Novartis Investigative Site	Arezzo	AR
Italy	Novartis Investigative Site	Busto Arsizio	VA
Italy	Novartis Investigative Site	Cagliari	CA
Italy	Novartis Investigative Site	Cassano delle Murge	BA
Italy	Novartis Investigative Site	Catania	CT
Italy	Novartis Investigative Site	Cernusco sul Naviglio	MI
Italy	Novartis Investigative Site	Chioggia	VE
Italy	Novartis Investigative Site	Latina	LT
Italy	Novartis Investigative Site	Legnano	MI
Italy	Novartis Investigative Site	Lodi	LO
Italy	Novartis Investigative Site	Matera	Mount
Italy	Novartis Investigative Site	Messina	ME
Italy	Novartis Investigative Site	Orbassano	TO
Italy	Novartis Investigative Site	Piacenza	PC
Italy	Novartis Investigative Site	Pordenone	PN
Italy	Novartis Investigative Site	Pozzuoli
Italy	Novartis Investigative Site	Reggio Emilia	RE
Italy	Novartis Investigative Site	Roma	RM
Italy	Novartis Investigative Site	Roma	RM
Italy	Novartis Investigative Site	Roma	RM
Italy	Novartis Investigative Site	Roma	RM
Italy	Novartis Investigative Site	San Benedetto del Tronto	AP
Italy	Novartis Investigative Site	Sassari	SS
Italy	Novartis Investigative Site	Scandiano	RE
Italy	Novartis Investigative Site	Siena	SI
Italy	Novartis Investigative Site	Siracusa	SR
Italy	Novartis Investigative Site	Torino	TO
Italy	Novartis Investigative Site	Torino	TO
Italy	Novartis Investigative Site	Treviglio	BG
Italy	Novartis Investigative Site	Verona	VR
Italy	Novartis Investigative Site	Vibo Valentia	VV
Italy	Novartis Investigative Site	Vicenza	VI
Latvia	Novartis Investigative Site	Daugavpils
Lithuania	Novartis Investigative Site	Kaunas	LTU
Lithuania	Novartis Investigative Site	Kaunas	LT
Lithuania	Novartis Investigative Site	Klaipeda
Lithuania	Novartis Investigative Site	Vilnius
Poland	Novartis Investigative Site	Bilgoraj
Poland	Novartis Investigative Site	Gdansk
Poland	Novartis Investigative Site	Grodzisk Mazowiecki
Poland	Novartis Investigative Site	Kielce
Poland	Novartis Investigative Site	Krakow
Poland	Novartis Investigative Site	Krakow
Poland	Novartis Investigative Site	Krakow	POL
Poland	Novartis Investigative Site	Lubin
Poland	Novartis Investigative Site	Lublin
Poland	Novartis Investigative Site	Oswiecim
Poland	Novartis Investigative Site	Rzeszow
Poland	Novartis Investigative Site	Tarnobrzeg
Poland	Novartis Investigative Site	Tarnow
Poland	Novartis Investigative Site	Walbrzych
Portugal	Novartis Investigative Site	Almada
Portugal	Novartis Investigative Site	Barreiro
Portugal	Novartis Investigative Site	Braga
Portugal	Novartis Investigative Site	Lisboa
Portugal	Novartis Investigative Site	Lisboa
Portugal	Novartis Investigative Site	Matosinhos
Portugal	Novartis Investigative Site	Setubal
Portugal	Novartis Investigative Site	Vila Franca de Xira
Romania	Novartis Investigative Site	Bucharest	Jud Cluj
Romania	Novartis Investigative Site	Bucharest
Romania	Novartis Investigative Site	Bucuresti	District 4
Romania	Novartis Investigative Site	Craiova	Jud. Iasi
Romania	Novartis Investigative Site	Sibiu
Romania	Novartis Investigative Site	Tirgoviste
Russian Federation	Novartis Investigative Site	Chelyabinsk
Russian Federation	Novartis Investigative Site	Chelyabinsk
Russian Federation	Novartis Investigative Site	Chita
Russian Federation	Novartis Investigative Site	Gatchina
Russian Federation	Novartis Investigative Site	Izhevsk
Russian Federation	Novartis Investigative Site	Kazan
Russian Federation	Novartis Investigative Site	Kazan
Russian Federation	Novartis Investigative Site	Kirov
Russian Federation	Novartis Investigative Site	Krasnoyarsk
Russian Federation	Novartis Investigative Site	Moscow
Russian Federation	Novartis Investigative Site	Moscow
Russian Federation	Novartis Investigative Site	Moscow
Russian Federation	Novartis Investigative Site	Moscow
Russian Federation	Novartis Investigative Site	Moscow
Russian Federation	Novartis Investigative Site	Novosibirsk
Russian Federation	Novartis Investigative Site	Penza
Russian Federation	Novartis Investigative Site	Petrozavodsk
Russian Federation	Novartis Investigative Site	Rostov-on-Don
Russian Federation	Novartis Investigative Site	Ryazan
Russian Federation	Novartis Investigative Site	Saint-Petersburg
Russian Federation	Novartis Investigative Site	Saratov
Russian Federation	Novartis Investigative Site	St.-Petersburg
Russian Federation	Novartis Investigative Site	Tyumen
Russian Federation	Novartis Investigative Site	Ufa
Russian Federation	Novartis Investigative Site	Vladivostok
Russian Federation	Novartis Investigative Site	Volgograd
Russian Federation	Novartis Investigative Site	Yaroslavl
Russian Federation	Novartis Investigative Site	Zelenograd, Moscow Region
Serbia	Novartis Investigative Site	Belgrade
Serbia	Novartis Investigative Site	Belgrade
Serbia	Novartis Investigative Site	Belgrade
Serbia	Novartis Investigative Site	Kamenica
Serbia	Novartis Investigative Site	Nis
Serbia	Novartis Investigative Site	Niska Banja
Slovakia	Novartis Investigative Site	Brezno
Slovakia	Novartis Investigative Site	Dunajska Streda	Slovak Republic
Slovakia	Novartis Investigative Site	Poprad
Slovakia	Novartis Investigative Site	Skalica	Slovak Republic
Slovakia	Novartis Investigative Site	Trencin
Slovakia	Novartis Investigative Site	Zvolen	Slovak Republic
Slovenia	Novartis Investigative Site	Celje
Slovenia	Novartis Investigative Site	Jesenice
Slovenia	Novartis Investigative Site	Ljubljana
Slovenia	Novartis Investigative Site	Murska Sobota
Spain	Novartis Investigative Site	Alcorcon	Madrid
Spain	Novartis Investigative Site	Alicante	Comunidad Valenciana
Spain	Novartis Investigative Site	Alicante	Comunidad Valenciana
Spain	Novartis Investigative Site	Alzira	Comunidad Valenciana
Spain	Novartis Investigative Site	Barcelona	Catalunya
Spain	Novartis Investigative Site	Bilbao	Pais Vasco
Spain	Novartis Investigative Site	Caceres	Extremadura
Spain	Novartis Investigative Site	Cartagena	Murcia
Spain	Novartis Investigative Site	El Palmar	Murcia
Spain	Novartis Investigative Site	Fuenlabrada	Madrid
Spain	Novartis Investigative Site	Galdakano	Pais Vasco
Spain	Novartis Investigative Site	Granada	Andalucia
Spain	Novartis Investigative Site	Granada	Andalucia
Spain	Novartis Investigative Site	La Coruna	Galicia
Spain	Novartis Investigative Site	La Laguna	Santa Cruz De Tenerife
Spain	Novartis Investigative Site	Las Palmas de Gran Canaria	Las Palmas De G.C
Spain	Novartis Investigative Site	Leon
Spain	Novartis Investigative Site	Lleida	Cataluna
Spain	Novartis Investigative Site	Madrid
Spain	Novartis Investigative Site	Madrid
Spain	Novartis Investigative Site	Malaga	Andalucia
Spain	Novartis Investigative Site	Manises	Valencia
Spain	Novartis Investigative Site	Murcia
Spain	Novartis Investigative Site	Oviedo	Asturias
Spain	Novartis Investigative Site	Salamanca	Castilla Y Leon
Spain	Novartis Investigative Site	Sanlucar de Barrameda	Andalucia
Spain	Novartis Investigative Site	Santiago de Compostela	Galicia
Spain	Novartis Investigative Site	Sevilla	Andalucia
Spain	Novartis Investigative Site	Sevilla	Andalucia
Spain	Novartis Investigative Site	Sevilla	Andalucia
Spain	Novartis Investigative Site	Soria	Castilla Y Leon
Spain	Novartis Investigative Site	Terrassa	Catalunya
Spain	Novartis Investigative Site	Toledo	Castilla La Mancha
Spain	Novartis Investigative Site	Valencia	Comunidad Valenciana
Spain	Novartis Investigative Site	Valencia	Comunidad Valenciana
Spain	Novartis Investigative Site	Valencia	Comunidad Valenciana
Spain	Novartis Investigative Site	Valencia	Comunidad Valenciana
Spain	Novartis Investigative Site	Villamartin	Cadiz
Spain	Novartis Investigative Site	Zaragoza
Switzerland	Novartis Investigative Site	Basel
Switzerland	Novartis Investigative Site	Geneve 14
Switzerland	Novartis Investigative Site	Liestal
Switzerland	Novartis Investigative Site	Lugano
United Kingdom	Novartis Investigative Site	Barnet
United Kingdom	Novartis Investigative Site	Cardiff
United Kingdom	Novartis Investigative Site	Dorchester	Dorset
United Kingdom	Novartis Investigative Site	Dundee
United Kingdom	Novartis Investigative Site	Durham	County Durham
United Kingdom	Novartis Investigative Site	Gateshead	Tyne And Wear
United Kingdom	Novartis Investigative Site	Liverpool
United Kingdom	Novartis Investigative Site	London
United Kingdom	Novartis Investigative Site	Peterborough	GBR
United Kingdom	Novartis Investigative Site	Swindon

Sponsors (1)

Lead Sponsor	Collaborator
Novartis Pharmaceuticals

Countries where clinical trial is conducted

Austria,  Belgium,  Bulgaria,  Croatia,  Czechia,  Estonia,  Finland,  France,  Germany,  Greece,  Hungary,  Iceland,  Italy,  Latvia,  Lithuania,  Poland,  Portugal,  Romania,  Russian Federation,  Serbia,  Slovakia,  Slovenia,  Spain,  Switzerland,  United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Percentage of Participants With Worsening Heart Failure (WHF) / All Cause of Deaths Through Day 5	In-hospital WHF through Day 5 post-randomization included worsening signs and/or symptoms of heart failure that required an intensification of intravenous therapy for heart failure or mechanical ventilation, renal or circulatory support. A central event adjudication committee was appointed to oversee the WHF primary endpoint adjudication.	5 days
Secondary	Percentage of Participants With In-hospital Worsening Heart Failure/All-Cause Death/Readmission for Heart Failure Through Day 14	WHF/death/readmission for heart failure through Day 14. WHF/deaths through Day 5 were adjudicated and confirmed by the Clinical Endpoint Committee, WHF/deaths after Day 5 through Day 14 and readmission through Day 14 were as reported by the investigators.	14 days
Secondary	Percentage of Participants With Persistent Sign or Symptoms of Heart Failure / Non-Improvement at Any Post Baseline Visit Through Day 5	Persistent or non-improvement in any signs or symptoms of HF at any post baseline visit up to Day 5.	5 days
Secondary	Percentage of Participants With Renal Deterioration at Any Post Baseline Visit Through Day 14	Renal deterioration is defined as > or = 0.3 mg/dL increase from screening in serum creatinine.	14 days
Secondary	Length of Index Hospital Stay	Length of stay (in hours) is defined as the index hospitalization discharge date and time minus the index hospitalization start date and time.	30 Days
Secondary	Percentage of Participants With Adverse Events as Assessment of Safety and Tolerability of Serelaxin in AHF Patients		Adverse Events (AE): 5 Days / Serious Adverse Events (SAE): 14 days / All cause deaths 30 days
Secondary	Change From Baseline in Health-related Quality of Life Index Value, Assessed by EuroQoL EQ-5D-5L Questionnaire.	EQ-5D-5L is a questionnaire designed to assess health status in adults consisting of 5 dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression). The results were converted into a single index value using UK as the reference country for all countries. Range -0.3 (worst possible state) to 1 (best possible state).	Baseline, Day 5, Day 14